Answers are grounded in this paper and cite their sources.
In 2022, the Uruguayan Health Technology Evaluation Agency (AETSU) published an evidence synthesis report in which the results of randomized controlled clinical studies that have used different cannabinoid-based products for the treatment of chronic pain were analyzed; the authors concluded that "current evidence does not show that, in patients with chronic pain under standard treatment, the addition of medicinal cannabis is effective in reducing the intensity of pain compared to placebo." In the present review, we aim to critically appraise the results from that report, highlighting strengths and weaknesses and contrasting its results with those of other existing systematic reviews and clinical practice guidelines. This review concludes by providing a bioethical context to the results from the AETSU report, highlighting possible impacts on the medical care and care of patients with chronic pain. Relevant aspects related to the holistic and multidisciplinary management of this chronic pain are underlined, providing a more useful and informative resource for clinical practice and decision making.
No takes yet. Share an insight, caveat, or question.
Cubillos et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: